Format

Send to

Choose Destination
Lancet. 2003 Sep 27;362(9389):1065-71.

Hepatitis A booster vaccination: is there a need?

Author information

1
Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Control and Prevention of Viral Hepatitis, Unit of Epidemiology and Social Medicine, University of Antwerp, 2610 , Antwerp, Belgium. pierre.vandamme@ua.ac.be

Abstract

Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against the infection. However, there is no worldwide consensus on how long protection will last or whether there will be a need for hepatitis A virus (HAV) booster vaccinations in the future. In most countries, booster-vaccination policy is guided by manufacturers' recommendations, national authorities, or both. In June, 2002, a panel of international experts met to review the long-term immunogenicity and protection conferred by HAV vaccine in different population groups. Data have shown that after a full primary vaccination course, protective antibody amounts persist beyond 10 years in healthy individuals, and underlying immune memory provides protection far beyond the duration of anti-HAV antibodies. The group concluded that there is no evidence to lend support to HAV booster vaccination after a full primary vaccination course in a healthy individual. However, further investigations are needed before deciding if boosters can be omitted in special patient-groups.

PMID:
14522539
DOI:
10.1016/S0140-6736(03)14418-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center